The Use of Novel and Unique Biofield Energy Healing Treatment for the Improvement of Poorly Bioavailable Compound, Berberine in Male Sprague Dawley Rats
American Journal of Clinical and Experimental Medicine
Volume 5, Issue 4, July 2017, Pages: 138-144
Received: May 20, 2017; Accepted: Jun. 1, 2017; Published: Jul. 14, 2017
Views 1855      Downloads 75
Authors
Alice Branton, Trivedi Global, Inc., Henderson, Nevada, USA
Snehasis Jana, Trivedi Science Research Laboratory Pvt. Ltd., Bhopal, Madhya Pradesh, India
Article Tools
Follow on us
Abstract
Berberine, an isoquinoline alkaloid based herbal medicine, is widely used as nutraceutical supplement for the prevention and treatment of various diseases viz. hypolipidemic, hypoglycemic, antiarrhythmic, antineoplastic, etc. The intestinal absorption and oral bioavailability of berberine is very low and almost negligible in humans. In this study, the relative oral bioavailability of berberine was studied, and the effects of The Trivedi Effect®-Energy of Consciousness Healing Treatment on animals and berberine were investigated through the measurement of plasma concentrations after oral administration in rats. The test item, berberine chloride was divided into two parts. One part was denoted as the control without any Biofield Energy Healing Treatment, while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Healing Treatment by renowned Biofield Energy Healer, Alice Branton. Additionally, one group of animals also received Consciousness Energy Healing Treatment per se by Alice under similar conditions. Berberine oral formulations were made and administrated by oral gavage at a dose of 150 mg per kg in groups viz. G1 (untreated berberine), G2 (Biofield Treated berberine) and G3 (Biofield Treated animals were received untreated berberine) group. The results showed that berberine had a very low oral plasma exposure of 179.92 ng/mL in the control group. The Biofield Energy Healing Treatment significantly enhanced the relative oral exposure (AUC0–t) of berberine by 233.40% and 35.62% in G2 and G3 groups, respectively compared to the control group. The Biofield Energy Treatment also improved plasma peak concentration (Cmax) of berberine by 37.7 and 1.4 times, in G2 and G3 groups, respectively compared to the control group. The absorption rate constant (Ka) of berberine in Biofield Energy Treatment group significantly increased by 100% (p < 0.05) in G2 group as compared to the control group (G1). The apparent oral plasma clearance of berberine decreased significantly (p < 0.01) by 81%, and 50% in G2 group and G3 group, respectively as compared to the control group. The enhanced bioavailability of berberine might be due to the alteration its physicochemical properties and thermal properties by Biofield Energy Treatment. Biofield Energy Healing Treatment is considered as an innovative strategy which opens new avenues to overcome poorly absorbed drug/nutraceuticals/herbal extracts and can also improve the therapeutic performance of orally active molecules. Thereby, the Biofield Energy Treated berberine chloride having improved bioavailability can significantly increase in antibacterial, anticancer, antidiabetic, anti-obesity, anti-ischemia, memory and cognition, inhibition of metabolic syndrome and neurodegenerative diseases.
Keywords
Absorption Enhancer, Berberine Chloride, Bioavailability, P-glycoprotein, Biofield Energy Healing Treatment, Relative Oral Exposure
To cite this article
Alice Branton, Snehasis Jana, The Use of Novel and Unique Biofield Energy Healing Treatment for the Improvement of Poorly Bioavailable Compound, Berberine in Male Sprague Dawley Rats, American Journal of Clinical and Experimental Medicine. Vol. 5, No. 4, 2017, pp. 138-144. doi: 10.11648/j.ajcem.20170504.16
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Inbaraj JJ, Kukielczak B, Bilski P, Sandvik S, Chignell C (2001) Photochemistry and photocytotoxicity of alkaloids from Goldenseal (Hydrastis canadensis L.) Berberine. Chem Res Toxicol 14: 1529-1534.
[2]
Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y (2009) Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 126: 5-17.
[3]
Singh A, Duggal S, Kaur N, Singh J (2010) Berberine alkaloid with wide spectrum of pharmacological activities. J Nat Prod 3: 64-75.
[4]
Chen C, Yu Z, Li Y, Fichna J, Storr M (2014) Effects of Berberine in the gastrointestinal tract – A review of actions and therapeutic implications. Am J Chin Med 42: 1053-1070.
[5]
Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K (2000) Synergy in a medicinal plant: Antimicrobial action of Berberine potentiated by 50 -methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 97: 1433-1437.
[6]
Diogo CV, Machado NG, Barbosa IA, Serafim TL, Burgeiro A, et al. (2011) Berberine as a promising safe anti-cancer agent - is there a role for mitochondria? Curr Drug Targets 12: 850859.
[7]
Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, Issandou M. (2006) Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. Journal of Lipid Research 47: 12811288.
[8]
Zhou XQ, Zeng XN, Kong H, Sun XL (2008) Neuroprotective effects of berberine on stroke models in vitro and in vivo. Neurosci Lett 447: 3136.
[9]
Abd El-Wahab AE, Ghareeb DA, Sarhan EE, Abu-Serie MM, El Demellawy MA (2013) In vitro biological assessment of berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement Altern Med 13: 218.
[10]
Zeng XH, Zeng XJ, Li YY (2003) Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 92: 173-176.
[11]
Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX, Wang GJ (2010) Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos 38: 1779-1784.
[12]
Gupta PK, Hubbard M, Gurley B, Hendrickson HP (2009) Validation of a liquid chromatography-tandem mass spectrometric assay for the quantitative determination of hydrastine and berberine in human serum. J Pharm Biomed Anal 49: 1021-1026.
[13]
Chen W, Fan D, Meng L, Miao Y, Yang S, Weng Y, He H, Tang X (2012) Enhancing effects of chitosan and chitosan hydrochloride on intestinal absorption of berberine in rats. Drug Dev Ind Pharm 38: 104-110.
[14]
Zhang Y, Cui YL, Gao LN, Jiang HL (2013) Effects of beta-cyclodextrin on the intestinal absorption of berberine hydrochloride, a P-glycoprotein substrate. Int J Biol Macromol 59: 363-371.
[15]
Maeng HJ, Yoo HJ, Kim IW, Song IS, Chung SJ, Shim CK (20020 P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. Journal of Pharmaceutical Sciences 91: 2614-2621.
[16]
Movaffaghi Z, Farsi M (2009) Biofield therapies: Biophysical basis and biological regulations. Complement Ther Clin Pract 15: 35-37.
[17]
Shenefelt PD (2014) Energy medicine in dermatology. In: Norman RA, Shenefelt PD, Rupani RN, editors. Integrative Dermatology. Oxford University Press, New York, NY, USA.
[18]
Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) Antimicrobial sensitivity pattern of Pseudomonas fluorescens after biofield treatment. J Infect Dis Ther 3: 222.
[19]
Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Phenotypic and biotypic characterization of Klebsiella oxytoca: An impact of biofield treatment. J Microb Biochem Technol 7: 203-206.
[20]
Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) An effect of biofield treatment on Multidrug-resistant Burkholderia cepacia: A multihost pathogen. J Trop Dis 3: 167.
[21]
Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, Mondal SC, Jana S (2015) Antimicrobial susceptibility pattern, biochemical characteristics and biotyping of Salmonella paratyphi A: An impact of biofield treatment. Clin Microbiol 4: 215.
[22]
Trivedi MK, Nayak G, Patil S, Tallapragada RM, Latiyal O (2015) Studies of the atomic and crystalline characteristics of ceramic oxide nano powders after biofield treatment. Ind Eng Manage 4: 161.
[23]
Trivedi MK, Patil S, Tallapragada RM (2013) Effect of biofield treatment on the physical and thermal characteristics of silicon, tin and lead powders. J Material Sci Eng 2: 125.
[24]
Trivedi MK, Patil S, Tallapragada RM (2013) Effect of biofield treatment on the physical and thermal characteristics of vanadium pentoxide powder. J Material Sci Eng S 11: 001.
[25]
Trivedi MK, Patil S, Tallapragada RM (2015) Effect of biofield treatment on the physical and thermal characteristics of aluminium powders. Ind Eng Manage 4: 151.
[26]
Patil SA, Nayak GB, Barve SS, Tembe RP, Khan RR (2012) Impact of biofield treatment on growth and anatomical characteristics of Pogostemon cablin (Benth.). Biotechnology 11: 154-162.
[27]
Altekar N, Nayak G (2015) Effect of biofield treatment on plant growth and adaptation. J Environ Health Sci 1: 1-9.
[28]
Shinde V, Sances F, Patil S, Spence A (2012) Impact of biofield treatment on growth and yield of lettuce and tomato. Aust J Basic Appl Sci 6: 100-105.
[29]
Sances F, Flora E, Patil S, Spence A, Shinde V (2013) Impact of biofield treatment on ginseng and organic blueberry yield. Agrivita J Agric Sci 35: 22-29.
[30]
Lenssen AW (2013) Biofield and fungicide seed treatment influences on soybean productivity, seed quality and weed community. Agricultural Journal 8: 138-143.
[31]
Trivedi MK, Mohan TRR (2016) Biofield energy signals, energy transmission and neutrinos. American Journal of Modern Physics 5: 172-176.
[32]
Trivedi MK, Branton A, Trivedi D, Nayak G, Balmer AJ, Anagnos D, Kinney JP, Holling JM, Balmer JA, Duprey-Reed LA, Parulkar VR, Panda P, Sethi KK, Jana S (2017) Evaluation of the Energy of Consciousness Healing Treated Withania somnifera (Ashwagandha) root extract using LC-MS, GC-MS, and NMR spectroscopy. American Journal of Biomedical and Life Sciences 5 (2), 16-25.
[33]
Trivedi MK, Branton A, Trivedi D, Nayak G, Balmer AJ, Anagnos D, Kinney JP, Holling JM, Balmer JA, Duprey-Reed LA, Parulkar VR, Panda P, Sethi KK, Jana S (2017) Evaluation of physicochemical, spectral, thermal and behavioral properties of the Biofield Energy Healing Treated sodium selenate, Science Journal of Chemistry 5 (2), 12-22.
[34]
Hua W, Ding L, Chen Y, Gong B, He J, Xu G (2007) Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 44: 931-937.
[35]
Chen W, Miao Y, Fan DJ, Yang SS, Lin X, Meng LK, Tang X (2011) Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS Pharm Sci Tech 12: 705-711.
[36]
Wang T, Wang N, Song H, Xi X, Wang J, et al. (2011) Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. Eur J Pharm Sci 44: 127-135.
[37]
Fan D, Wu X, Dong W, Sun W, Li J, et al. (2013) Enhancement by sodium caprate and sodium deoxycholate of the gastrointestinal absorption of berberine chloride in rats. Drug Dev Ind Pharm 39: 1447-1456.
[38]
Battu SK, Repka MA, Maddineni S, Chittiboyina AG, Avery MA, Majumdar S (2010) Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. AAPS Pharm Sci Tech 11: 1466-475.
[39]
Benet LZ (2010) Predicting drug disposition via application of a Biopharmaceutics drug disposition classification system. Basic Clin Pharmacol Toxicol 106: 162-167.
[40]
Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY (2002) The involvement of Pglycoprotein in berberine absorption. Pharmacol Toxicol 91: 193-197.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186